Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Circulating tumor DNA (ctDNA) has emerged as a promising tool in the diagnosis, monitoring, and management of hepatocellular carcinoma (HCC). This non-invasive "liquid biopsy" technique offers several advantages in understanding and treating HCC.
In a study of 58 Chinese advanced HCC patients, ctDNA was detected in 89.7% of cases, demonstrating its high sensitivity.
The most frequently mutated genes identified in HCC through ctDNA analysis are:
In a study of HCC patients treated with neoadjuvant cemiplimab (an anti-PD-1 therapy), ctDNA changes correlated closely with tumor necrosis and relapse-free survival (RFS)
References:
Marron et al. 20…